Clinical Trials · NCT06858839
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Amgen
- Enrollment
- 3,853
- Start date
- Mar 2025
- Locations
- 243 sites, 17 countries
- Primary endpoint
- Percent Change From Baseline in Body Weight at Week 72